Latest News

CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021

* AYVAKIT has demonstrated significant anti-tumor activity in Chinese patients with PDGFRA D842V ...

2021-07-08 08:05 1493

CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer

* Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients w...

2021-06-28 08:05 2727

CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully impro...

2021-05-28 08:10 5909

CStone Pharmaceuticals Reports Financial Results and Business Highlights for Full-year 2020

SUZHOU, China, March 25, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leadin...

2021-03-25 22:03 2505

CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients

* GAVRETO has been approved for the treatment of adults with locally advanced or metastatic RET f...

2021-03-24 10:46 3484

ESMO ASIA Congress 2020 | CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLC

SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2020-11-23 09:30 2438

CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC

* Currently, there is no anti-PD-L1 monoclonal antibody approved for stage IV NSCLC inChina * A...

2020-11-12 10:58 2619

CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate

* CStone to acquire exclusive rights for development and commercialization outsideSouth Korea for...

2020-10-29 07:15 1788

CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)

* CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for dev...

2020-10-27 07:23 1539

CStone Announces Completion of $200 million Share Sale to Pfizer

SUZHOU, China, Oct. 12, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announce...

2020-10-12 08:05 4417

CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting

* CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%, a complete response (C...

2020-09-25 15:28 2718